CXCR4 and neoplasm: Since the administration of the CXCR4 inhibitor AMD3100 during the time of day when its expression was elevated in tumor‐infiltrated CD8+ T cells facilitated their dispersal from CAF‐dense regions within the tumor microenvironment, we investigated whether monotherapy with AMD3100, as well as combination therapy with AMD3100 and anti‐PD‐L1 antibodies, could improve anti‐tumor immune efficacy.